Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M115,820Revenue $M20,063Net Margin (%)25.7Z-Score2.4
Enterprise Value $M120,725EPS $6.7Operating Margin %30.9F-Score5
P/E(ttm))24.8Cash Flow Per Share $6.7Pre-tax Margin (%)27.8Higher ROA y-yN
Price/Book4.710-y EBITDA Growth Rate %11.7Quick Ratio3.9Cash flow > EarningsY
Price/Sales6.15-y EBITDA Growth Rate %7.9Current Ratio4.2Lower Leverage y-yY
Price/Cash Flow13.3y-y EBITDA Growth Rate %15.5ROA % (ttm)7.5Higher Current Ratio y-yN
Dividend Yield %1.7Insider Buy (3m)1ROE % (ttm)21.4Less Shares Outstanding y-yN
Payout Ratio %36.0Shares Outstanding M761ROI % (ttm)8.2Gross Margin Increase y-yN

Gurus Latest Trades with AMGN

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AMGNDaniel Loeb 2014-12-31 Add13.4%$130.45 - $171.64
($155.84)
$ 157.721%Add 705.66%10,675,000
AMGNJoel Greenblatt 2014-12-31 Add0.01%$130.45 - $171.64
($156.25)
$ 157.721%Add 285.93%10,393
AMGNVanguard Health Care Fund 2014-12-31 Reduce-0.51%$130.45 - $171.64
($155.84)
$ 157.721%Reduce -20.54%5,580,485
AMGNMario Gabelli 2014-12-31 Reduce-0.02%$130.45 - $171.64
($155.84)
$ 157.721%Reduce -34.11%39,500
AMGNDaniel Loeb 2014-09-30 Add1.39%$115.39 - $144.01
($130.57)
$ 157.7221%Add 194.44%1,325,000
AMGNJean-Marie Eveillard 2014-09-30 Buy 0.25%$115.39 - $144.01
($130.57)
$ 157.7221%New holding, 714178 sh.714,178
AMGNKen Fisher 2014-09-30 Add0.02%$115.39 - $144.01
($130.57)
$ 157.7221%Add 83.59%156,629
AMGNRuane Cunniff 2014-09-30 Buy $115.39 - $144.01
($130.57)
$ 157.7221%New holding, 1617 sh.1,617
AMGNVanguard Health Care Fund 2014-09-30 Reduce-0.32%$115.39 - $144.01
($130.57)
$ 157.7221%Reduce -12.75%7,022,755
AMGNJohn Hussman 2014-09-30 Reduce-0.23%$115.39 - $144.01
($130.57)
$ 157.7221%Reduce -50%25,000
AMGNJoel Greenblatt 2014-09-30 Reduce-0.01%$115.39 - $144.01
($130.57)
$ 157.7221%Reduce -72.9%2,693
AMGNDaniel Loeb 2014-06-30 Buy 0.65%$110.29 - $126.07
($115.72)
$ 157.7236%New holding, 450000 sh.450,000
AMGNJoel Greenblatt 2014-06-30 Buy 0.02%$110.29 - $126.07
($115.72)
$ 157.7236%New holding, 9938 sh.9,938
AMGNMario Gabelli 2014-06-30 Add0.02%$110.29 - $126.07
($115.72)
$ 157.7236%Add 85.28%60,335
AMGNKen Fisher 2014-06-30 Add0.01%$110.29 - $126.07
($115.72)
$ 157.7236%Add 71.02%85,316
AMGNJohn Hussman 2014-06-30 Reduce-0.93%$110.29 - $126.07
($115.72)
$ 157.7236%Reduce -66.67%50,000
AMGNMario Gabelli 2014-03-31 Add0.01%$113.48 - $127.47
($121.04)
$ 157.7230%Add 37.87%32,565
AMGNKen Fisher 2014-03-31 Add0.01%$113.48 - $127.47
($120.95)
$ 157.7230%Add 754.67%49,887
AMGNDodge & Cox 2014-03-31 Reduce$113.48 - $127.47
($121.04)
$ 157.7230%Reduce -22.59%105,757
AMGNPRIMECAP Management 2014-03-31 Reduce-0.46%$113.48 - $127.47
($121.04)
$ 157.7230%Reduce -9.42%32,161,744
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AMGN is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
AMGN Daniel Loeb 2014-12-3110,675,0001.4115.3+705.66%
AMGN Joel Greenblatt 2014-12-3110,39300.01+285.93%
AMGN Ruane Cunniff 2014-12-311,61700
AMGN John Hussman 2014-12-3125,00000.4
AMGN PRIMECAP Management 2014-12-3131,613,8804.175.1-0.57%
AMGN Ken Fisher 2014-12-31154,4390.020.05-1.4%
AMGN Jean-Marie Eveillard 2014-12-31651,8550.090.25-8.73%
AMGN Dodge & Cox 2014-12-3166,4270.010.01-8.89%
AMGN Vanguard Health Care Fund 2014-12-315,580,4850.742.1-20.54%
AMGN Mario Gabelli 2014-12-3139,5000.010.03-34.11%
AMGN Mark Hillman 2013-12-317,91201.4-1.95%
Premium Most recent portfolio changes are included for Premium Members only!


AMGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Bradway Robert AChairman, CEO and President 2015-02-11Sell22,000$152.693.29view
HERRINGER FRANK CDirector 2015-02-05Buy3,000$152.293.57view
de Carbonnel FrancoisDirector 2014-12-03Sell3,000$168.01-6.12view
Patton Cynthia MSVP & CCO 2014-08-05Sell2,644$127.9723.25view
Harper Sean EEVP, Research & Development 2014-08-05Sell14,000$127.2923.91view
Dittrich Thomas J.W.VP, Finance & CAO 2014-05-21Sell4,130$112.8339.79view
Bradway Robert AChairman, CEO and President 2014-05-12Buy894$111.7741.11view
Michael A KellyActing CFO 2014-04-28Sell2,065$110.4542.8view
Piacquad DavidSVP, Business Development 2014-03-10Sell0$042.8view
de Carbonnel FrancoisDirector 2014-03-06Sell1,000$126.6924.49view

Press Releases about AMGN :

    Quarterly/Annual Reports about AMGN:

    News about amgn:

    Articles On GuruFocus.com
    Third Point LLC: Fourth Quarter Letter To Investors Feb 13 2015 
    Daniel Loeb Comments on Amgen Inc Feb 10 2015 
    Dan Loeb Fourth Quarter Investor Letter Feb 10 2015 
    Daniel Loeb’s Third Point Q4 2014 Investor Letter Feb 09 2015 
    New Guru Jana Partners' Newest Stock Buys Jan 22 2015 
    Pharmaceutical Companies Amgen and Kite Partner for Cancer Therapy Jan 07 2015 
    Druckenmiller Adds Healthcare Stocks to Portfolio Dec 15 2014 
    Endonovo Therapeutics Receives Final Commissioned Report Recommendations Regarding FDA Regulatory Pa Dec 02 2014 
    Dividend Aristocrats In Focus Part 45: AbbVie Nov 24 2014 
    Amgen: Stronger Drug Portfolio with Acquisition Oct 28 2014 

    More From Our Partners
    Amgen's Kyprolis Under EU Review - Analyst Blog Feb 28 2015 - ZACKS

    More From Other Websites
    Amgen's Kyprolis Under EU Review - Analyst Blog Feb 28 2015
    Stock Market Video Analysis for Week Ending 2/27/15 Feb 28 2015
    Final Glance: Biotechnology companies Feb 27 2015
    Bellevue city manager: Keeping Expedia in Bellevue a 'top priority' Feb 27 2015
    Expedia may move to Amgen's former Seattle campus Feb 27 2015
    Midday Glance: Biotechnology companies Feb 27 2015
    Early Glance: Biotechnology companies Feb 27 2015
    The Zacks Analyst Blog Highlights: Pharmacyclics, Celgene, Amgen and Regeneron - Press Releases Feb 27 2015
    Amgen Announces The European Medicines Agency Acceptance Of Kyprolis® (Carfilzomib) Marketing... Feb 27 2015
    Amgen Receives Positive CHMP Opinion For Use Of Vectibix® (panitumumab) As First-Line Treatment In... Feb 27 2015
    9:00 am Amgen announces that the CHMP of the EMA adopted a positive opinion to extend the marketing... Feb 27 2015
    Amgen Receives Positive CHMP Opinion For Use Of Vectibix® (panitumumab) As First-Line Treatment In... Feb 27 2015
    Amgen Announces Results from Phase 3 Clinical Study Comparing AMG 416/ONO-5163 with Cinacalcet... Feb 27 2015
    Amgen Announces the European Medicines Agency Acceptance of Kyprolis® (carfilzomib) Marketing... Feb 26 2015
    Amgen Announces The European Medicines Agency Acceptance Of Kyprolis® (Carfilzomib) Marketing... Feb 26 2015
    Short Sellers Come Back To Biotech Stocks Feb 26 2015
    AMGEN INC Financials Feb 26 2015
    Amgen Reports Encouraging Late-Stage Data on AMG 416 - Analyst Blog Feb 26 2015
    Biotech Stock Roundup: Pharmacyclics Up on Buyout Rumors, Celgene Drug Label Expanded - Analyst Blog Feb 26 2015
    Short Sellers Increase Bets Against Biotech as Shares Continue to Rise Feb 26 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK